Conv. Plasma
Nigella Sativa

All famotidine studies
Meta analysis
study COVID-19 treatment researchFamotidineFamotidine (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The association between famotidine and in-hospital mortality of patients with COVID-19

Kuno et al., Journal of Medical Virology, doi:10.1002/jmv.27375
Oct 2021  
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 0% Improvement Relative Risk Famotidine for COVID-19  Kuno et al.  LATE TREATMENT Is late treatment with famotidine beneficial for COVID-19? PSM retrospective 9,565 patients in the USA (Mar 2020 - Mar 2021) No significant difference in mortality Kuno et al., J. Medical Virology, October 2021 Favorsfamotidine Favorscontrol 0 0.5 1 1.5 2+
Famotidine for COVID-19
25th treatment shown to reduce risk in October 2021
*, now with p = 0.00026 from 30 studies, recognized in 2 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments.
PSM retrospective 9,565 COVID-19 hospitalized patients in the USA, 1,593 receiving famotidine, showing no significant difference in mortality.
risk of death, no change, OR 1.00, p = 0.97, treatment 1,593, control 7,972, RR approximated with OR.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Kuno et al., 11 Oct 2021, retrospective, propensity score matching, USA, peer-reviewed, 4 authors, study period 1 March, 2020 - 30 March, 2021.
This PaperFamotidineAll
The association between famotidine and in‐hospital mortality of patients with COVID‐19
MD Toshiki Kuno, Matsuo So, Mai Takahashi, Natalia N Egorova
Journal of Medical Virology, doi:10.1002/jmv.27375
Famotidine has been considered to be a potential treatment for COVID-19 but the current data is conflicting. This retrospective study was conducted by utilizing data of 9565 COVID-19 hospitalized patients. Patients treated with and without famotidine were matched by propensity score using a 1:1 matching scheme. A total of 1593 patients (16.7%) received famotidine. In-hospital mortality was similar in patients treated with and without famotidine in the propensity-matched cohorts (28.3% vs. 28.2%, p = 0.97), which remains similar irrespective of severity or concomitant treatment by steroids. Famotidine treatment was not associated with a lower risk of in-hospital mortality of COVID-19 patients.
CONFLICT OF INTERESTS The authors declare that there are no conflict of interests. ETHICS STATEMENT This study was approved by the Institutional Review Boards (#2000495) and conducted in accordance with the principles of the Declaration of Helsinki. The waiver of patients' informed consent was also approved by the institutional review boards. AUTHOR CONTRIBUTIONS Toshiki Kuno, Mai Takahashi, and Natalia N. Egorova had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Toshiki
Castells, Butterfield, Mast cell activation syndrome and mastocytosis: initial treatment options and long-term management, J Allergy Clin Immunol Pract
Freedberg, Conigliaro, Wang, Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study, Gastroenterology
Kuno, Miyamoto, Iwagami, Ishimaru, Takahashi et al., The association of remdesivir and in-hospital outcomes for COVID-19 patients treated with steroids, J Antimicrob Chemother
Kuno, So, Miyamoto, Iwagami, Takahashi et al., The association of COVID-19 antibody with in-hospital outcomes in COVID-19 infected patients, J Med Virol, doi:10.1002/jmv.27260
Kuno, So, Takahashi, Egorova, U shape association of hemoglobin level with in-hospital mortality for COVID-19 patients, J Thromb Thrombolysis
Malone, Tisdall, Smith, COVID-19: famotidine, histamine, mast cells, and mechanisms, Front Pharmacol
Mather, Seip, Mckay, Impact of famotidine use on clinical outcomes of hospitalized patients with COVID-19, Am J Gastroenterol
Mukherjee, Bhattacharya, Bojkova, Famotidine inhibits toll-like receptor 3-mediated inflammatory signaling in SARS-CoV-2 infection, J Biol Chem
Shoaibi, Fortin, Weinstein, Berlin, Ryan, Comparative effectiveness of famotidine in hospitalized COVID-19 patients, Am J Gastroenterol
So, Kabata, Takahashi, Egorova, Kuno, The association of inhaled corticosteroid before admission and survival of patients with COVID-19, J Aerosol Med Pulm Drug Deliv
Sterne, Murthy, Diaz, Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis, JAMA
{ 'indexed': {'date-parts': [[2022, 1, 20]], 'date-time': '2022-01-20T06:41:20Z', 'timestamp': 1642660880036}, 'reference-count': 11, 'publisher': 'Wiley', 'issue': '3', 'license': [ { 'start': { 'date-parts': [[2021, 10, 11]], 'date-time': '2021-10-11T00:00:00Z', 'timestamp': 1633910400000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': ''}, { 'start': { 'date-parts': [[2021, 10, 11]], 'date-time': '2021-10-11T00:00:00Z', 'timestamp': 1633910400000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': ''}], 'content-domain': {'domain': [''], 'crossmark-restriction': True}, 'short-container-title': ['Journal of Medical Virology'], 'published-print': {'date-parts': [[2022, 3]]}, 'DOI': '10.1002/jmv.27375', 'type': 'journal-article', 'created': {'date-parts': [[2021, 10, 7]], 'date-time': '2021-10-07T04:21:17Z', 'timestamp': 1633580477000}, 'page': '1186-1189', 'update-policy': '', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': ['The association between famotidine and in‐hospital mortality of patients with COVID‐19'], 'prefix': '10.1002', 'volume': '94', 'author': [ { 'ORCID': '', 'authenticated-orcid': False, 'given': 'Toshiki', 'family': 'Kuno', 'sequence': 'first', 'affiliation': [ { 'name': 'Division of Cardiology, Montefiore Medical Center Albert ' 'Einstein College of Medicine New York New York USA'}, { 'name': 'Department of Medicine, Icahn School of Medicine at Mount Sinai ' 'Mount Sinai Beth Israel New York New York USA'}]}, { 'given': 'Matsuo', 'family': 'So', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine, Icahn School of Medicine at Mount Sinai ' 'Mount Sinai Beth Israel New York New York USA'}]}, { 'given': 'Mai', 'family': 'Takahashi', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Medicine, Icahn School of Medicine at Mount Sinai ' 'Mount Sinai Beth Israel New York New York USA'}]}, { 'given': 'Natalia N.', 'family': 'Egorova', 'sequence': 'additional', 'affiliation': [ { 'name': 'Department of Population Health Science and Policy Icahn School ' 'of Medicine at Mount Sinai New York New York USA'}]}], 'member': '311', 'published-online': {'date-parts': [[2021, 10, 11]]}, 'reference': [ {'key': 'e_1_2_6_2_1', 'doi-asserted-by': 'publisher', 'DOI': '10.3389/fphar.2021.633680'}, { 'key': 'e_1_2_6_3_1', 'doi-asserted-by': 'publisher', 'DOI': '10.14309/ajg.0000000000000832'}, { 'key': 'e_1_2_6_4_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1053/j.gastro.2020.05.053'}, { 'key': 'e_1_2_6_5_1', 'doi-asserted-by': 'publisher', 'DOI': '10.14309/ajg.0000000000001153'}, {'key': 'e_1_2_6_6_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1001/jama.2020.17023'}, {'key': 'e_1_2_6_7_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jaip.2019.02.002'}, { 'key': 'e_1_2_6_8_1', 'article-title': 'The association of COVID‐19 antibody with in‐hospital outcomes in ' 'COVID‐19 infected patients', 'author': 'Kuno T', 'year': '2021', 'journal-title': 'J Med Virol'}, {'key': 'e_1_2_6_9_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/jac/dkab256'}, { 'key': 'e_1_2_6_10_1', 'first-page': '1', 'article-title': 'U shape association of hemoglobin level with in‐hospital mortality for ' 'COVID‐19 patients', 'volume': '2', 'author': 'Kuno T', 'year': '2021', 'journal-title': 'J Thromb Thrombolysis'}, {'key': 'e_1_2_6_11_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1089/jamp.2021.0020'}, {'key': 'e_1_2_6_12_1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jbc.2021.100925'}], 'container-title': ['Journal of Medical Virology'], 'original-title': [], 'language': 'en', 'link': [ { 'URL': '', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'application/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': '', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 1, 19]], 'date-time': '2022-01-19T16:21:34Z', 'timestamp': 1642609294000}, 'score': 1, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 10, 11]]}, 'references-count': 11, 'journal-issue': {'issue': '3', 'published-print': {'date-parts': [[2022, 3]]}}, 'alternative-id': ['10.1002/jmv.27375'], 'URL': '', 'archive': ['Portico'], 'relation': {}, 'ISSN': ['0146-6615', '1096-9071'], 'issn-type': [{'value': '0146-6615', 'type': 'print'}, {'value': '1096-9071', 'type': 'electronic'}], 'subject': ['Infectious Diseases', 'Virology'], 'published': {'date-parts': [[2021, 10, 11]]}, 'assertion': [ { 'value': '2021-08-16', 'order': 0, 'name': 'received', 'label': 'Received', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2021-10-01', 'order': 1, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'publication_history', 'label': 'Publication History'}}, { 'value': '2021-10-11', 'order': 2, 'name': 'published', 'label': 'Published', 'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop